Nipro closing in on stem cell cure for spinal cord injuriesNikkei Asian ReviewOSAKA — Medical equipment maker Nipro could commercialize next year a stem-cell-based treatment seen allowing people with spinal cord injuries to walk again. The Osaka-based… Continue reading
Dr. Roboz on Challenges With CAR T-cell Therapy in ALLOncLiveGail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clini… Continue reading
5 Developments With Cancer ImmunotherapyAJMC.com Managed Markets NetworkWith clinical trials evaluating several different combinations of immunotherapy agents, can we use predictive biomarkers as an early sign of patient response? A study recently publ… Continue reading
Drug Discovery & Development |
Agilis Biotherapeutics, Gene Therapy Research Institution Enter Strategic Partnership
Drug Discovery & Development Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution Co, Ltd. (GTRI), a corporation with the … |
Daily Mail |
Controversial CRISPR gene-editing could replace daily insulin injections in diabetes patients
Daily Mail Controversial CRISPR gene-editing could replace daily insulin injections in diabetes patients, new research suggests. Mice whose skin cells are genetically altered to express the glucose-regulating hormone GLP1 gain around half as much weight when … CRISPR-treated skin graft used to treat diabetes in miceNew Atlas CRISPR skin grafts could replace insulin injections for diabetesNew Scientist CRISPR Gene Therapy via Skin Grafts Treats Obesity and Diabetes in MiceGenetic Engineering & Biotechnology News Science Daily –CNBC –The Scientist all 20 news articles » |
Madison.com |
Here’s How Intrexon Might Prove Me Wrong
Madison.com Synthetic biology toolkit: One of the most difficult things about developing the technology platform is figuring out how to work with gas fermentation at the lab scale. Intrexon spent a lot of time developing completely new equipment to accomplish this … |
nwitimes.com |
Here’s How Intrexon Might Prove Me Wrong
nwitimes.com Synthetic biology toolkit: One of the most difficult things about developing the technology platform is figuring out how to work with gas fermentation at the lab scale. Intrexon spent a lot of time developing completely new equipment to accomplish this … |